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Abbreviations
PTB = Preterm birth
FTB = Fullterm birth
LBW = Low birthweight
NBW = Normal birthweight
WHO = World Health Organisation
TSAT = Transferrin saturation
MDG = Millennium development goal
GBS = Group B Streptococci 
EONS = Early onset neonatal sepsis
YICSS = Young Infants Clinical Signs Studies
KGH = Kanifing General Hospital
MRCG = Medical Research Council Unit The Gambia at LSHTM
KMC = Kanifing Municipal Council
UIBC = Unbound iron-binding capacity
IL6 = Interleukin 6
IL22 = Interleukin 22
sTfR = Soluble transferrin receptor
CRP = C-reactive protein
AGP = Alpha 1-acid glycoprotein
HIV = Human immunodeficiency virus
TB = Tuberculosis
EDTA = Ethylenediaminetetraacetic acid
V1 = Venous bleed 1
V2 = Venous bleed 2
IM = Intramuscular
ELISA = Enzyme-linked immunosorbent assay
ID = Identification
CRF = Case report form
eCRF = Electronic case report form
ANOVA = Analysis of variance
IDE = Integrated development environment
CyTOF = Cytometry by time of flight
STAT3 = Signal transducer and activator of transcription 3
TLR = Toll-like receptor
SOP = Standard operating procedure
OD = Optical density
WBC = White blood cell
LPS = Lipopolysaccharide
Introduction
Neonatal infections – challenges in low-income settings
Neonatal infection is the third largest cause of death in chil-
dren under-five worldwide and is an ongoing major global 
public health challenge (Sustainable Development Goal 3.2)1. 
Between 1990 and 2016 maternal and under-five child mortal-
ity has decreased by half2. However, the proportion of neonatal 
deaths among under-five deaths increased from 37% (1990) to 
44% (2013)3,4. Today, approximately 2.8 million children die 
annually during the neonatal period – the first 28 days of life. 
Of these, 73% die within the first six days of life3. An increas-
ing proportion of child deaths are in sub-Saharan Africa5, with 
60–80% of newborn deaths occurring in low birthweight (LBW) 
neonates (<2500g at birth)6. 95% of all LBW neonates are born 
in low-income countries7. However, the situation is likely to be 
worse than documented, as neonatal deaths in developing 
countries are commonly under reported and the records 
commonly contain errors8,9. It is estimated that about one third of 
deaths in the first month of life, are caused by infections includ-
ing bacterial sepsis, meningitis, pneumonia, neonatal tetanus, and 
diarrhoea10.
Evidence is lacking on the aetiology of neonatal infections in 
developing countries, especially from community settings11,12. 
However, the limited data suggests that Klebsiella species, 
Escherichia coli, and Staphylococcus aureus are common causes 
of early onset sepsis (EONS)13–15. The available antibiotic suscep-
tibility data suggests that pathogens associated with neonatal sepsis 
in developing countries are often resistant to WHO-recommended 
empiric antibiotics13,16. Antibiotic resistance has emerged with 
potency over the last few decades due to a multitude of com-
plex reasons. Antibiotic overuse, inappropriate prescribing, inad-
equate diagnostics, extensive agricultural use, availability of 
few new antibiotics, and the ease of transportation of resistant 
bacteria are among the factors contributing to the rise. Equally, 
bacteria have the ability to rapidly mutate (with or without drug 
selection pressure) and horizontally transfer genetic mate-
rial between species (i.e. non-human pathogens) of bacteria17,18. 
Neonates are particularly at risk from antibiotic resistant 
organisms because they generally succumb before alternative 
antibiotic regimes can be tried.
Diagnosis of neonatal sepsis with high specificity remains chal-
lenging in developing countries. A widely used tool developed 
by the World Health Organization Young Infants Clinical Signs 
Studies (YICSS), which includes seven clinical signs to aid 
diagnosis, has only a 85% sensitivity and 75% specificity for 
severe bacterial infection during the first week of life19. Microbio-
logical identification of a pathogen isolated from blood cultures 
often has higher specificity, but microbiological laboratory facili-
ties are frequently lacking in low-income settings19. With this 
all in mind, there is an immediate need to improve our under-
standing of neonatal blood-borne infections and develop novel 
therapies that could enhance immunological protection possibly 
via boosting innate immune mechanisms.
Nutritional immunity
Iron is critical for the human host and most pathogens. Iron 
is one of the most important factors in the host-pathogen battle 
for resources. Bacteria and other pathogens have evolved a wide 
variety of mechanisms to acquire iron from the nutrient rich 
host (e.g. siderophores and iron specific channels)20 to aid 
growth and virulence, with a number of iron acquisition genes 
concentrated on high pathogenicity islands21.
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Nutritional immunity describes the normal physiological innate 
processes used by the host to combat infection by limiting 
nutrient availability. Key among these processes is the abil-
ity to rapidly decrease the circulating concentration of iron (and 
other transition metals) in response to an infection22. The hypof-
erremia of inflammation is mediated by the hormone, hepcidin. 
Research completed in 2000–2001 by three independent 
research groups led to the discovery of the hepcidin hormone, 
and the important function it plays in many aspects of iron 
metabolism23–25. Hepcidin is now understood to be the master 
regulator of iron homeostasis. Unlike any other micronutrient, 
iron is regulated by a hormone that responds to both infection 
and nutritional status. The host inflammatory mediators, IL626, 
IL2227 and Type 1 interferon28, have been found to increase tran-
scription of hepcidin through several Toll-like receptor (TLR) 
ligands29 and STAT3 signalling30,31 resulting in decreased sys-
temic iron concentrations in the circulation. This multifaceted 
mechanism limits nutrient availability to extracellular invad-
ing microorganisms32. The system is well documented in 
mouse models33–35, but less so in human studies. However, it is 
clear that humans with excessive levels of serum iron (e.g. due 
to hemochromatosis) are predisposed to infection with iron- 
dependent species of bacteria36,37.
Neonatal hypoferremia
Although iron metabolism in adults and older children is well 
studied, the kinetics of iron handling in the early neonatal period, 
a time of intense physiological change, are poorly understood38. 
Childbirth results in a neonate moving from a semi-allogeneic, 
protected and nearly sterile environment to one that is abundant 
in a diverse array of microbes. The delivery process is the initial 
focal point for the mass bacterial colonisation of the skin and gas-
trointestinal tract of the neonate39,40. Neonates are known to have 
very low levels of immunological memory and possess an imma-
ture immune system41. Post-natal iron metabolism in neonates 
is controlled by an array of different signals, such as hypoxia, 
erythropoietic drive, maternal and foetal iron stores42. A number 
of studies have investigated serum iron, transferrin saturation 
(TSAT), ferritin and haemoglobin levels at the time of birth using 
cord blood as a proxy for early neonatal blood43,44. A recent pro-
spective study showed neonates born preterm compared to early-
term had higher serum iron concentrations in umbilical blood, 
which was inversely correlated with levels of serum hepcidin45. 
A similar study has also shown that small-for-gestational-age 
neonates and neonates born by elective caesarean have lower 
levels of hepcidin44. Previous work has shown that serum iron 
and TSAT decreases between birth and the first 6–12 hours post- 
partum in full term, healthy vaginally delivered newborns46,47.
The study described here will shed light on the effects of pre-
maturity and birthweight on body iron distribution immedi-
ately after birth and during the first week of life. Free ferric 
and ferrous iron (i.e. transferrin bound iron), haem-based iron 
molecules and their chaperone proteins (haem-hemopexin and 
haemoglobin-haptoglobin) will also be investigated.
Study objectives
The primary study objective is to characterize in detail how full 
term, preterm and low birthweight neonates modulate serum 
iron in the first 24 hours of life. We hypothesize that prema-
ture and/or low birthweight babies have a defect in their ability 
to sequester iron at 6–24 hours after birth in comparison to 
full term neonates with normal birthweight.
The secondary objectives are:
I.      Characterise how iron metabolism, handling and 
recycling differs between full term, preterm and low 
birthweight neonates at birth and during the first 
24 hours of life.
II.     Describe iron metabolism, handling and recycling in full 
term neonates at birth and during the first 7 days of life.
III.    Determine if sera from preterm and low birthweight 
neonates supports a greater level of ex-vivo growth 
of microorganisms that are common causes of neo-
natal sepsis in Africa and The Gambia (Staphylococ-
cus aureus, Klebsiella pneumoniae, Escherichia coli, 
Group B Streptococcus, Streptococcus pneumoniae and 
Salmonella enterica serovar Typhimurium (S. Typhimu-
rium hereafter)) in comparison to sera from full term, 
normal birthweight neonates.
IV.    Characterize frequencies and functionality of neu-
trophils, monocytes, dendritic cells, NK cells, B cells and 
T cells (D8 and CD4) in cord blood from full term, 
premature and low birthweight neonates.
Protocol
Study site
Study participants will be recruited from Kanifing General 
Hospital (formally Serrekunda General Hospital), in the Kanifing 
region of The Gambia, West Africa. Serrekunda is a large 
town, forming a peri-urban area with a population of around 
340,000, and is 13km to the southwest of the capital, Banjul. 
Serrekunda was originally made up of nine villages that have 
merged into a sprawling urban area. Annually, Kanifing General 
Hospital (KGH) provides antenatal care to 500–700 pregnant 
mothers. Mothers receiving antenatal care at other local health-
care facilities increase the total number of births at the hospital 
to 3500–4500 per year. The percentage of these that are live, low 
birthweight neonates (<2.5kg) is approximately 10%. Speci-
men samples will be subjected to primary processing on-site at 
KGH, followed by transport to Medical Research Council Unit 
The Gambia at LSHTM (MRCG) for storage and analysis.
Participants
In total, 450 healthy newly born neonates will be identified dur-
ing delivery at the Kanifing General Hospital Maternity Ward 
(Figure 1) starting in July 2017. Pregnant mothers must be over 
the age of eighteen years. After informed consent is obtained, 
neonates who meet the inclusion criteria will be enrolled 
into the study. For inclusion in the study, neonates must be 
healthy, medically stable, greater than 32 weeks gestational age 
and weigh more than 2000g. To be considered preterm (PTB) the 
neonates will be < 37 weeks gestational age (assessed by New 
Ballard Score48) and ≥ 32 weeks gestational age. All neonates 
with a gestational age ≥37 weeks will be considered full term 
(FTB). To be considered low birthweight (LBW) the 
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Figure 1. Main study flow chart of all study procedures and exclusion criteria. Group A will contain neonates characterised by preterm 
birth and low birthweight (PTB+LBW); Group B will contain neonates characterised by preterm birth and normal birthweight (PTB+NBW); 
Group C will contain neonates characterised by full term birth and low birthweight (FTB+LBW); Groups D1, D2 and D3 will all contain 
babies characterised by full term birth and normal birthweight (FTB+NBW). In this study, preterm is defined <37 weeks gestation and low 
birthweight is <2500g. Exclusion criteria (α): Father refused, mother refused, family/escort refused, communication not possible or mother 
with severe disabilities. Exclusion criteria (β): Antibiotics or antimalarials given before delivery (<24 hours), referred to tertiary level health 
facility, absconded, known HIV-positive, severe pre-eclampsia, receiving TB treatment, antepartum haemorrhage, recent blood transfusion 
(within the last month), no foetal heartbeat, mother <18 years, refusal, recruited to another study and emergency caesarean section. 
Exclusion criteria (γ): Recruited to another study on-site, refusal, blood transfusion given in labour, antibiotics or antimalarials given during 
labour, neonate requires resuscitation (1 min APGAR), neonatal weight <2000g, neonate born breech, neonate born via vacuum delivery, 
neonate born caesarean section, foetal stillbirth, macerated stillbirth and major congenital malformations. Exclusion criteria (δ): Failed cord 
blood collection (serum tubes), failed cord blood collection (EDTA), cord blood processed >3 hours, neonate requires resuscitation (10 min 
APGAR), absconded and route 2B refusal. Exclusion criteria (ε): Mother birth check refusal, father birth check refusal, family escort birth 
check refusal, mother <18 years, recruited to another study on-site, antibiotics or antimalarials given to mother before delivery (<24 hours), 
neonate has had surgery, neonates sibling twin was recruited, neonate given antibiotics (other than tetracycline eye ointment), neonate 
given iron supplementation, neonatal sickness (tone, activity, feeding, heart rate, respiratory rate, abnormal anterior fontanelle), neonatal 
temperature (<36.5°C or >37.5°C), major congenital malformations (neonate), New Ballard Score (<32 weeks), failed V1 (serum), failed V1 
(EDTA), failed V1 (both EDTA and serum), mother V1 bleed refusal, father V1 bleed refusal, and family/escort V1 bleed refusal. Exclusion 
criteria (ζ): neonatal sickness (tone, activity, feeding, heart rate, respiratory rate, abnormal anterior fontanelle), neonatal temperature (<36.5°C 
or >37.5°C), neonate has had surgery, neonate given antibiotics (other than tetracycline eye ointment), neonate given iron supplementation, 
failed V2 bleed, Mother community/V2 bleed refusal, father community/V2 bleed refusal, and family community/V2 bleed refusal.
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neonates will weigh < 2500g. All neonates weighing ≥ 2500 g will 
be considered normal birthweight (NBW).
The study groups are:
Group A (PTB+LBW): Neonates who are both preterm and low 
birthweight.
Group B (PTB+NBW): Neonates who are preterm and normal 
birthweight.
Group C (FTB+LBW): Neonates who are full term but low 
birthweight.
Group D (FTB+NBW): Neonates who are full term and normal 
birthweight.
In addition to the main study, 300 FTB neonates of the 450 
neonates will also be included into a sub-study, which aims 
to describe serum iron markers in full term babies (Group D, 
FTB+NBW only) over the first week of life.
Study design
This is a proof-of-concept, observational cohort study (Groups 
A, B, C and D) with an embedded short prospective cohort 
study (Group D divided into D1, D2 and D3).
Entry evaluation
Consent and enrolment. There are two routes into the study enrol-
ment (Figure 2). Pregnant mothers who are receiving antena-
tal care on-site at KGH, will be approached at an antenatal visit 
and voluntarily sensitised to the study requirements and proto-
col (Route 1). Pregnant women, who are sensitised will not be 
required at that point to give written or verbal consent. This 
group will be provided with study information sheets and encour-
aged to discuss study participation with their family. When the 
pregnant woman returns to KGH Maternity Ward to deliver 
(some mothers will choose to deliver at other healthcare facili-
ties), she will be asked to read the full study information sheet 
(or have it read to her by a study nurse if she is not literate) 
and provide formal written consent to the study involvement 
for their neonate (see Extended data49–51).
Route 2 will provide an alternative route of enrolment for preg-
nant mothers, that would like their neonate to be part of the 
study but have been receiving antenatal care at another facil-
ity before delivering at KGH maternity ward. In route 2, healthy, 
pregnant women will enter the KGH ward to deliver and will be 
approached to provide written formal consent to umbilical cord 
blood collection and storage only. No testing or laboratory proc-
esses will be conducted on their sample, until full study consent 
is gained post-delivery. The cord blood sample will be stored at 
4°C (within the maternity ward), until the mother’s pain and 
discomfort subside (2–6 hours post-delivery). At this point, 
the mother and/or father will be invited to provide written formal 
consent on full study enrolment. If, at this point, mother and/or 
father refuse full study consent post-delivery, the previously col-
lected personal information and umbilical cord sample will be 
safely discarded.
Pre-delivery screening
In both Route 1 and Route 2 enrolment, mothers must provide 
written consent before assessment of personal information (ante-
natal card) and questioning can begin. After consenting, mothers 
will be asked for their demographic information and their per-
sonal contact details. Pregnant mothers will be excluded from 
the study if they are below the age of 18 years, have no foetal 
heartbeat detected upon admission, known to be HIV-positive, 
in receipt of Mycobacterium tuberculosis therapy, taken antibiot-
ics in the last 24 hours, had a blood transfusion in the last month, 
suffering from severe pre-eclampsia or antepartum haemor-
rhage, or in another research study. Mothers can refuse to be part 
of the study at any stage of the study protocol. Pregnant women 
that are referred at this point to a tertiary level healthcare facility, 
will be excluded from the study.
Delivery procedures, post-delivery screening and umbilical 
cord blood collection
Delivery procedures and screening. Study nurses will assist 
clinical KGH maternity ward staff in the delivery process and 
collect data via electronic case report form (eCRF) on their 
designated study tablets. Neonates will be excluded at the delivery 
stage of the study for the following reasons: major congenital 
malformations (not including polydactylism), blood transfusions 
given to mother or neonate, severe birth asphyxia (requiring 
resuscitation), neonates born via breech, vacuum or via caesarean 
section, or a birthweight <2000g. After the delivery stage of the 
study protocol, neonates can be excluded from the study follow-
ing the detection of infection or illness (information gained from 
full blood count analysis or review of systems). Neonates will 
also be removed from the study protocol, if medication is 
given (not including intramuscular vitamin K, tetracycline eye 
ointment or any immunisations). All medication that is given 
to mothers and neonates will be recorded. Mothers will be able 
to refuse study participation at any stage. Mothers that deliver 
multiple newborns will only be invited to consent and enrol 
one of their neonates into the study.
Umbilical cord blood collection. Once the neonate is fully deliv-
ered, one-minute delayed cord clamping will be used (following 
World Health Organisation (WHO) policy52). During the one-
minute delay, the one-minute APGAR score will be conducted. 
If the neonate requires resuscitation, the neonate will be excluded 
from the study. After the umbilical cord has been removed and 
cleaned, a trained study nurse will identify the umbilical arter-
ies and the umbilical vein. Blood will be collected from both. 
The tubes will be placed in the cool box for 1-3 hours before 
transfer to the study laboratory for primary processing. If the 
mother is enrolled by route 2, the mother will be asked to 
provide written consent to full study recruitment before the 
sample is sent for primary laboratory processing.
Hospital assessment and 1st venous blood draw
Hospital health assessment (study recruitment and group 
allocation). At 6–24 hours post-delivery, recruited mothers 
and their neonates will be invited to a private consultation with 
the study research clinician. Further demographic data will 
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Figure 2. NeoInnate Study enrolment route and blood draw design. Group A contains neonates characterised by preterm birth and low 
birthweight (PTB+LBW); Group B contains neonates characterised by preterm birth and normal birthweight (PTB+NBW); Group C contains 
neonates characterised by full term birth and low birthweight (FTB+LBW); Groups D1, D2 and D3 all contain babies characterised by full term 
birth and normal birthweight (FTB+NBW).
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be collected, along with a photograph of the antenatal card to 
gather gestational age data (fundal height, last menstrual period 
and ultrasound), mother’s last haemoglobin level before deliv-
ery (dated), known sickle cell status, neonate immunisations, and 
medication given to the mother (pre, during and post-delivery) 
and the neonate. A complete review of systems of the mother 
and neonate plus anthropometric data on the newborn will then 
be collected. Neuromuscular and physical maturation of each 
neonate will be assessed using the New Ballard Score48.
Neonates will be excluded if they score less than 32 weeks of 
gestation. From this assessment, the neonate will be assigned 
to a specific study group. If the neonate is allocated to the 
Group D (FTB+NBW) group, the neonate will be allocated to a 
randomised bleed group (≥24 hours - <80 hours (Group D1); 
≥80 hours - <136 hours (Group D2); and ≥136 - <192 hours 
(Group D3). Failure to meet the inclusion criteria at this stage 
of the study protocol, will result in exclusion from the study.
1st venous blood draw (all neonates). A blood sample will 
be collected from all neonates that have passed the inclusion 
criteria in the hospital health assessment. Immediately after the 
health assessment, a venous blood draw will be performed (6–24 
hours post-delivery). PTB and/or LBW neonates will donate 
2ml of venous blood. FTB+NBW neonates will donate 3.5ml 
of venous blood. All samples will reach the laboratory within 
three hours post collection for primary processing.
Community health assessment and 2nd venous blood draw
Community health assessment. Study nurses will visit all moth-
ers or enrolled neonates at their homes at least once. At that 
visit, a physical examination of the neonate will be completed. 
The following information will also be collected: neonatal 
immunisation history, a complete review of systems of the 
mother and baby, and any medication given to the mother or 
neonate since delivery. Mothers will also be provided with health 
education and study contact details (should the neonate become 
unwell).
2nd venous blood draw Group D (FTB+NBW) only. At this point, 
if the mother and neonate are deemed to have passed the screen-
ing process and the neonate is in Group D, then the neonate 
will have its second and last venous blood draw (3.5ml). All 
samples will reach the laboratory within three hours post collection 
for primary processing.
Laboratory evaluations
Blood samples. Whole blood samples will be assessed for: full 
haematology panel (using a Medonic M20M GP), glucose-6-
phosphate dehydrogenase deficiency and sickle trait. All serum 
samples collected will be assessed by ELISA for the follow-
ing: IL6, IL22, free haem, hepcidin, hemopexin, lipocalin-2, 
lactoferrin, and foetal haemoglobin. Additionally, serum ferri-
tin, serum iron, UIBC, soluble transferrin receptor (sTfR), trans-
ferrin, C-reactive protein (CRP), haptoglobin, and alpha 1-acid 
glycoprotein (AGP) will be assessed using a fully automated 
biochemistry analyser (Cobas Integra 400 plus) Additionally, 
umbilical WBC will be processed and analysed for exploratory 
secondary analysis 4.
Bacterial growth assays. Ex vivo growth of bacteria (includ-
ing clinical and laboratory isolates of Staphylococcus aureus, 
Klebsiella pneumoniae, Escherichia coli, Enterobacter spp., 
Enterococcus spp., and Salmonella Typhimurium) in participant 
serum as in Cross et al. (2015)53 will be performed.
Study outcomes
The primary outcome variables will be TSAT (transferrin 
saturation) and serum iron.
The secondary outcome variables will be hepcidin; hemo-
pexin; haptoglobin; IL22; free serum haem and haemoglobin; 
foetal haemoglobin; lactoferrin; lipocalin-2; IL6; C-reactive 
protein; alpha-1-acid glycoprotein; transferrin concentration; 
soluble transferrin receptor; unbound iron-binding capacity; 
ferritin; haemoglobin; WBCs types and numbers in cord blood 
samples and ex vivo bacterial growth.
Data entry, handling, storage and security
All protocol-required field data will be captured electroni-
cally on an electronic eCRF or a paper case report form (CRF) 
that will be completed for each included participant. After giv-
ing written consent the pregnant women will be given a study 
identification number, which will be used in all future data-
sets for subject anonymity. Field data will be collected ver-
bally and from antenatal cards by study nurses. Collected data 
will be entered in real time using eCRFs developed on top of a 
REDCap (Research Electronic Data Capture) database and pub-
lished on Samsung Galaxy Tab 3 SM-T111 handheld devices. 
Collected data will be transported to the database via a direct 
secure connection over the 4G mobile network. Laboratory related 
data will be extracted directly from laboratory equipment and 
uploaded to the database. Any data collected on the paper format 
will be double entered by a trained data entry clerk. The local 
co-investigator will review all forms and identify any errors 
prior to data entry or to marking data as complete. The study 
data will also be validated through automated and manual vali-
dation methods implemented in the study database applica-
tion system. The study database will be custom-developed. All 
paper CRF will be stored in a locked file archive. Electronic 
data will be stored on the local dedicated server maintained at 
MRCG. The study will be conducted in compliance with Good 
Clinical Practice. Study personal security measures will include 
controlled access limited to authorised users only, physi-
cal security, remove identifiable information (anonymization), 
avoidance of third-party cloud storage and password protection.
Sample size and power
This study will target recruitment of 150 ‘’exposed” neonates 
which will include a target of 50 neonates in each Group A, 
B and C. 300 neonates will be recruited for Group D (“unex-
posed”). The study will have constraints from time, budget, 
loss to follow up, haemolysis during sample collection, insuf-
ficient blood volume and the distribution of new births in each 
group at the Kanifing General Hospital. 
Based on this, we have run simulations (Stata/IC 15.1) to 
calculate the power to detect a range of differences comparing 
groups for example Groups D and A with respect to the primary 
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outcomes TSAT and serum iron. We did not calculate power 
for the secondary outcomes, which are considered exploratory. 
The simulation was run using a linear regression model assum-
ing a lognormal distribution for the response variables TSAT and 
serum iron levels 6–24 hours after birth. Data from a previous 
study (Prentice S, personal communication) was used to obtain 
mean and SD estimates for TSAT and serum iron both at base-
line and 6–24 hours after birth. The predictor variables were 
the Groups (A–D) with Group D as the reference. The model 
was adjusted for the baseline (cord blood levels). We also 
examined the power assuming a normal distribution for TSAT 
(i.e. without log transformation). The significance level consid-
ered was 0.05 and the simulation was run for 100000 iterations. 
This process was repeated for the following four different sam-
ple size scenarios which we refer to as N1, N2, N3 and N4 
respectively:
N1) Group A=Group B =Group C =50 neonates
 N2) Group A=Group B =25 neonates and Group C =50 neonates
 N3) Group A=Group B =10 neonates and Group C =50 neonates
 N4) Group A=Group B =50 neonates and Group C =10 neonates
For all the above four cases, D=300.
The simulation results for the baseline adjusted model with 
log transformation show that for sample size scenario N1, the 
minimum mean differences that can be detected with 80% 
power were about 4% and 2.5 μmol/L for TSAT and serum iron 
respectively (Figure 3A and 3B). These correspond to effect 
sizes of 0.35 and 0.39 respectively. The power drops substan-
tially if smaller numbers were to be recruited as in scenarios N2 
(A=B=25) and N3 (A=B=10). Under N2 and N3, the minimum 
mean differences that can be detected with 80% would increase 
to about 5.8% and 9.1% for TSAT (Figure 3A) and 3.3 μmol/L 
and 5 μmol/L for serum iron (Figure 3B). The results for 
scenario N4 can be considered as subset of N1-N3 by 
rearranging Groups A, B and C.
Statistical analysis
The primary research objective is to examine if preterm and/or 
low birthweight neonates (“Exposed”) have a reduced ability 
to sequester iron at 6-24 hours after birth in comparison 
to full term neonates with normal birthweight (“Unexposed”)?
We hypothesize that FTB+NBW (Group D) neonates on 
average will have lower values of TSAT and serum iron 
compared to “Exposed” (PTB or LBW babies) (Figure 4). Ini-
tially, we will analyse all “Exposed” (Groups A+B+C) vs “Unex-
posed” (Group D). Each neonate will be further classified by his 
or her gestational age (premature vs. full term) and birthweight 
(low vs. normal) in a 2x2 table (Table 1). Linear regression 
models will be used in order to evaluate the difference in 
mean between each Group A-C and D; that is where D will be 
the reference group. TSAT and serum iron levels will be log 
transformed before fitting the models (if necessary). Both the 
unadjusted and adjusted (for the cord blood level) mean 
differences together with the 95% CI will be calculated.
In the second stage of analysis, we will assess the effect of poten-
tial confounding variables using the regression models. Covari-
ates to be considered include the specific time of measurement, 
demographic and health variables. The time effect may not be 
linear, and this will be investigated in the further regression 
models. To reduce the effects of multiple testing, data analy-
sis will be driven by a predefined primary study hypothesis. Any 
exploratory analyses conducted (in the absence of predefined 
study hypotheses) will be considered hypothesis-generating, rather 
than confirmatory. In order to reduce the levels of missing and 
inaccurately entered data into the database, all clinical, demo-
graphic and laboratory data will be entered in real time via elec-
tronic data capture, with automated and manual validation methods 
implemented. The study design does not provide for the recruit-
ment of equal numbers of subjects in each month of the 
year (or during the dry vs wet seasons). The Gambia has a 
higher birth rate during the months of September–December in 
comparison to other months54.
In order to remove this potential source of bias, we will adjust 
for month of birth and/or season in the regression analysis. If the 
missing data rates is more than 5%, we will consider imputa-
tion. The follow-up duration is relatively short. Thus, we expect 
little bias from loss to follow-up. If loss to follow-up rate is 
considerably different between groups, we will perform sensi-
tivity analyses to examine the robustness of results. We will also 
consider sensitivity analysis fitting a multivariate regression model 
where the main outcomes of interest (including TSAT, serum 
iron and hepcidin) will be jointly regressed to the same set of 
predictors.
The analysis for the secondary objectives are described below:
I.    Characterise how iron metabolism, handling and 
recycling differs between full term, preterm and low 
birthweight neonates at birth and during the first 
24 hours of life.
A similar strategy will be used as for the primary objective. Regres-
sion modelling will be used to evaluate the difference in means 
between each Group A-C and D; D will be the reference (“Unex-
posed”) group. The effects of potential confounding variables 
will also be assessed using further regression modelling.
II.    Describe iron metabolism, handling and recycling in 
full term neonates at birth and during the first 7 days 
of life.
Analysis of the longitudinal data will involve generalised esti-
mating equations incorporating time of measurement. We will 
include spline terms at each time point to evaluate the change in 
the outcomes (all primary and secondary outcome parameters) 
over time during the transition period from cord to 24–79; 80–135; 
136–192 hours after birth. Note that this will only include data 
collected from Group D neonates and will not be a comparison 
between Groups A–C and D neonates.
III.    Determine if sera from preterm and low birthweight 
neonates supports a greater level of ex-vivo growth of 
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Figure 3. Estimated power to detect a given difference between Groups A vs D based on simulation using a linear regression 
model adjusted for baseline for three sample size scenarios. N1 (Group A=Group B=Group C=50 neonates); N2 (Group A=Group 
B =25 neonates and Group C=50 neonates); N3 (Group A=Group B =10 neonates and Group C=50 neonates); N4 (Group A=Group B=50 
neonates and Group C =10 neonates).
Figure 4. An example of hypothetical scenario for TSAT 
values between the groups to be compared. In this example: 
(i) Time 0 refers to average cord blood levels (ii) Time 6-24 refers 
to the mean level in the 6-24 hour period after birth. (iii) T1, T2, 
represent TSAT in 1 and 2 above and ΔT=T2-T1 for full term, normal 
birthweight (Group D) (iv.) T1’, T2’and ΔT’=T2’-T1’ same as above 
but for the premature, low birthweight (Group A). Hypothesis: H0: 
T2=T2’ vs. HA: T2≠T2’.
Table 1. Four combinations 
in total for exposure: a: Pre, 
Low; b: Pre, Normal; c: Full, 




Term Pre A B
Full C D
microorganisms that are common causes of neona-
tal sepsis in Africa and The Gambia (Staphylococcus 
aureus, Klebsiella pneumoniae, Escherichia coli, Entero-
bacter spp., Enterococcus spp., and S. Typhimurium) 
in comparison to sera from FTB+NBW neonates.
The bacterial growth will be analysed in a similar method 
as described in Cross et al. (2015)53 in order to determine if 
changes in iron availability modulate the growth. Growth 












Here, the population size at the beginning of the growth 
curve is given by N0. The carrying capacity is given by K. 
The intrinsic growth rate of the population is r. We will gener-
ate the best fitting values of K, r and N0 for the growth curve 
data. Additionally, for each bacterium, we compare the time 
at which the population density reaches 12 K (inflection point), 
the fastest possible generation time (doubling time) and the 
area under the logistic curve obtained by taking the integral 
of the logistic equation. This will be used to assess growth 
curves from different sample types (Cord vs V1) and between 
the four study groups.
IV. Characterize frequencies and functionality of neutrophils, 
monocytes, dendritic cells, NK cells, B cells, T cells (D8 
and CD4) in cord blood from full term, premature and low 
birthweight neonates.
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Exploratory analysis will be conducted using linear regressions 
modelling.
Statistical analyses will be performed using STATA (Stata-
Corp. 2017. Stata Statistical Software: Release 15. College 
Station, TX: StataCorp LLC); R (R Foundation for Statistical 
Computing, Vienna, Austria.) and Data Desk (Data Description 
Inc Ithaca NY). All files used will have an accompanying data 
dictionary. Annotated STATA do-files or R files will be used to 
describe any data transformations and statistical tests used.
Dissemination of findings
The study results will be published in relevant peer-reviewed 
journals and key findings will be presented at international sci-
entific meetings. Data sharing will be in agreement with the 
sponsor policy on research data sharing and with the Bill & 
Melinda Gates Foundation Global Access requirements.
Study status
The study is in the data collection phase.
Discussion
Humans and bacteria are involved in an on-going tug of war over 
iron. Each side has evolved complicated and varied iron-acquisition 
mechanisms in an effort to turn the tide of war in their 
own favour55. Nutritional immunity describes the processes 
by which the human host tries to starve invading organisms of 
nutrients, especially iron.
This study aims to determine if premature and low birthweight 
babies have a defect in their ability to sequester iron during the 
first 24 hours of life. The study design will produce a detailed 
and extensive picture of iron metabolism in neonates. To our 
knowledge, no other study has tried to analyse such a large 
and diverse collection of iron and infection variables in 
neonates born in Sub Saharan Africa. The study will enrol sub-
jects who are all at an increased risk of neonatal infection, and 
subsequent sepsis and death.
A potential limitation of this study is the inadequacy of using 
the New Ballard Score as the only method of gestational aging. 
Original and New Ballard Score are reported to overestimated 
gestational age compared to ultrasound and in particular, misclas-
sify preterm infants as term newborns56. Additionally, newborn 
clinical assessments as a whole, tend to underestimate gesta-
tional age in growth-restricted neonates56. The gold standard of 
gestational aging is an ultrasound in the first trimester57. 
However, this procedure is rarely correctly completed in this 
study population. If it is documented on the mother’s antenatal 
records, care will be taken to record it. Limits of the study also 
include that HIV status, TB status and iron supplementation 
given are all gained from the antenatal records of the mother. 
Furthermore, antenatal records will not contain all information 
on medication given in every mothers’ pregnancy. As a result, 
care will be made to extensively question participants mother’s 
during verbal one-to-one consultation with our study research 
clinician.
In conclusion, our overarching study goal is to evaluate the likeli-
hood that novel products designed to induce hypoferremia (poten-
tially via mini-hepcidins58) may be useful in the future for the 
prevention of neonatal sepsis in high risk babies. This could be 
produced by a transient redistribution of iron away from the cir-
culation, thus applying a bacteriostatic brake on any bacteria that 
have crossed into the baby’s systemic circulation and hence 
boosting host survival in vulnerable newborns. We hope this may 
ultimately help reduce the use of antibiotics in maternal and 
neonatal wards worldwide.
Ethical approval
This study has been approved by The Gambia Government/MRC 
Joint Ethics Committee (no. SCC1525) and Ethics Commit-
tee of London School of Hygiene and Tropical Medicine (ref no. 
14316). The study procedures will be explained to the neonate’s 
mother/guardians orally or in writing. A neonate is only recruited 
into the study after the consent form has been signed/thumb 
printed by the mother/guardian.
This study was registered with clinicaltrials.gov (NCT03353051) 
on 27 November 2017.
Data availability
Underlying data
No data are associated with this article.
Extended data
Figshare: Cross et al. GatesOpen Research SCC1525v2__NeoIn-
nate_Participant Info&Consent form Route 1. https://doi.
org/10.6084/m9.figshare.8069195.v449
This project contains the following extended data:
•  SCC1525v2__NeoInnate_Consent form Route 1_v3 
Approved8Nov17.docx (Route 1 consent and informa-
tion sheet)
Figshare: Cross et al. GatesOpenResearch SCC1525v2_NeoInnate_
Consent form Route 2_Part 1_ (Umbilical Cord Blood Collection) 
- Labour Ward_v1.1-Approved 8Nov17. https://doi.org/10.6084/
m9.figshare.8069246.v150
This project contains the following extended data:
•  SCC1525v2_NeoInnate_Consent form Route 2_Part 
1_ (UCB Collection) - Labour Ward_v1.1-Approved 
8Nov17.docx (Route 2 consent and information sheet 
part 1)
Figshare: Cross et al. Gates Open Research SCC1525v2__NeoIn-
nate_Consent form Route 2_Part 2_(Post-Delivery) - ANC 
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Outside SGH v1-Approved 8Nov17. https://doi.org/10.6084/
m9.figshare.8069243.v151
This project contains the following extended data:
•  SCC1525v2__NeoInnate_Consent form Route 2_Part 
2_(Post-Delivery) - ANC Outside SGH v1-Approved 
8Nov17.docx (Route 2 consent and information sheet 
part 2)
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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